5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib
暂无分享,去创建一个
P. Choyke | W. Linehan | R. Srinivasan | B. Shuch | J. Shih | J. Nix | L. Stamatakis | M. Siddiqui | E. Singer | J. Friend | G. Hawks | D. Su